Filed revenue acceleration
Active · now 10.247651494449194%TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
Free trial
Ask AI to review this stock
Copy the prompt to get recent events, historical reactions, and a short research brief.
Tell your AI:
Help me set up FinLab and analyze INDV Indivior Pharmaceuticals Inc. Please read: https://finlab.finance/en/setup?stock=INDV
INDV
Indivior Pharmaceuticals Inc Healthcare As of 2026-07-20 Updated daily after market close
strong quality, premium valuation.
1 active signal
This page refreshes daily after the close. Add Indivior Pharmaceuticals Inc to your watchlist to track signal changes on your next visit.
Is Indivior Pharmaceuticals Inc a buy? Fundamentals and valuation first
-
Quality is top-tier. Operating margin ranks above roughly 83% of the liquid US common-stock universe. TTM ROE is about -174.3%.
-
Valuation is expensive. TTM P/E is in the 73th percentile, above most peers.
-
Recent volatility is moderate. 60-day annualized volatility is near the 35th percentile. Average 20-day dollar volume is about $74.5M.
-
Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.
Historical evidence
Signals active now
Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.
Market-wide momentum baseline
Across 96,530 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.31%, a 58.2% positive-return rate, and +2.95 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
52-week adjusted-price high
PendingAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
19 times historically; 60-day forward avg +4.21%, win rate 41.2%, beating the market by +1.98 pts on average.
Top-quintile 6-month momentum
PendingThe stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
24 times historically; 60-day forward avg +13.04%, win rate 62.5%, beating the market by +7.03 pts on average.
EPS surprise beat
PendingReported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.
10 times historically; 60-day forward avg +6.85%, win rate 55.6%, beating the market by +0.31 pts on average.
Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.